Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.7
4.6
Journals
Molecules
Special Issues
Pharmaceutical Nanotechnology: Drug Delivery Challenges
molecules-logo
Submit to Special Issue Submit Abstract to Special Issue Review for Molecules Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Pharmaceutical Nanotechnology: Drug Delivery Challenges

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: 31 August 2024 | Viewed by 1231

Special Issue Editors

Dr. Maria Antònia Busquets

E-Mail Website
Guest Editor
Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Avda. Joan XXIII, 27-31, 08028 Barcelona, Spain
Interests: colloidal systems; liposomes; Langmuir–Blodgett films; membrane models; drug delivery; surfaces; magnetic nanoparticles; prussian blue nanoparticles; liposomes; magnetoliposomes
Special Issues, Collections and Topics in MDPI journals
Dr. Alba Espargaró

E-Mail Website
Guest Editor
Department of Pharmacy, Pharmaceutical Technology, and Physical Chemistry Faculty of Pharmacy and Food Sciences University of Barcelona Avda Joan XIII, 27-31 08028 Barcelona, Spain
Interests: neuroprotective agents; neurodegeneration; neurodegenerative diseases; aggregation; protein aggregation; prion diseases; amyloid neuropathies

Special Issue Information

Dear Colleagues,

Poor biopharmaceutical characteristics of drug and biological barriers in the body affect whether the drug molecules reach the intended disease site. For instance, the solubility and permeability of a drug molecule affect its transportation through the cellular membranes, while their stability in the biological environment dictates residence time and efficacy. Nanomedicines, an innovation of nanotechnology, ferry the payload safely and effectively through several anatomical and physiological barriers to the target site. Furthermore, nanomedicines could be engineered to provide compound effects through ligand-mediated targeting and image-guided drug delivery at the disease site. With illustrative examples from scientific literature, we seek to emphasize the versatility of different nanosystems and their utility in disease therapy, spanning from preclinical development to approved products. Specific issues in drug approval, including quality-by-design and regulatory aspects, will be discussed in this Special Issue. Based on the advances in drug delivery and nanomaterial synthesis, there is a great future for nanomedicine in the diagnosis and treatment of several complex diseases.

This new Special Issue aims to publish a collection of reviews as well as original research papers devoted to drug delivery incorporating nanotechnology.

Dr. Maria Antònia Busquets
Dr. Alba Espargaró
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanotechnology
  • drug delivery

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

20 pages, 5376 KiB  
Article
β-Cyclodextrin Nanophotosensitizers for Redox-Sensitive Delivery of Chlorin e6
by Jaewon Jo, Ji Yoon Kim, Je-Jung Yun, Young Ju Lee and Young-IL Jeong
Molecules 2023, 28(21), 7398; https://doi.org/10.3390/molecules28217398 - 02 Nov 2023
Cited by 1 | Viewed by 904
Abstract
The aim of this study is to prepare redox-sensitive nanophotosensitizers for the targeted delivery of chlorin e6 (Ce6) against cervical cancer. For this purpose, Ce6 was conjugated with β-cyclodextrin (bCD) via a disulfide bond, creating nanophotosensitizers that were fabricated for the redox-sensitive delivery [...] Read more.
The aim of this study is to prepare redox-sensitive nanophotosensitizers for the targeted delivery of chlorin e6 (Ce6) against cervical cancer. For this purpose, Ce6 was conjugated with β-cyclodextrin (bCD) via a disulfide bond, creating nanophotosensitizers that were fabricated for the redox-sensitive delivery of Ce6 against cancer cells. bCD was treated with succinic anhydride to synthesize succinylated bCD (bCDsu). After that, cystamine was attached to the carboxylic end of bCDsu (bCDsu-ss), and the amine end group of bCDsu-ss was conjugated with Ce6 (bCDsu-ss-Ce6). The chemical composition of bCDsu-ss-Ce6 was confirmed with 1H and 13C NMR spectra. bCDsu-ss-Ce6 nanophotosensitizers were fabricated by a dialysis procedure. They formed small particles with an average particle size of 152.0 ± 23.2 nm. The Ce6 release rate from the bCDsu-ss-Ce6 nanophotosensitizers was accelerated by the addition of glutathione (GSH), indicating that the bCDsu-ss-Ce6 nanophotosensitizers have a redox-sensitive photosensitizer delivery capacity. The bCDsu-ss-Ce6 nanophotosensitizers have a low intrinsic cytotoxicity against CCD986Sk human skin fibroblast cells as well as Ce6 alone. However, the bCDsu-ss-Ce6 nanophotosensitizers showed an improved Ce6 uptake ratio, higher reactive oxygen species (ROS) production, and phototoxicity compared to those of Ce6 alone. GSH addition resulted in a higher Ce6 uptake ratio, ROS generation, and phototoxicity than Ce6 alone, indicating that the bCDsu-ss-Ce6 nanophotosensitizers have a redox-sensitive biological activity in vitro against HeLa human cervical cancer cells. In a tumor xenograft model using HeLa cells, the bCDsu-ss-Ce6 nanophotosensitizers efficiently accumulated in the tumor rather than in normal organs. In other words, the fluorescence intensity in tumor tissues was significantly higher than that of other organs, while Ce6 alone did not specifically target tumor tissue. These results indicated a higher anticancer activity of bCDsu-ss-Ce6 nanophotosensitizers, as demonstrated by their efficient inhibition of the growth of tumors in an in vivo animal tumor xenograft study. Full article
(This article belongs to the Special Issue Pharmaceutical Nanotechnology: Drug Delivery Challenges)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop